Howland Capital Management LLC Makes New $211,000 Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Howland Capital Management LLC purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 1st quarter, HoldingsChannel reports. The firm purchased 1,632 shares of the biotechnology company’s stock, valued at approximately $211,000.

Several other institutional investors also recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its position in Sarepta Therapeutics by 37.0% in the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after buying an additional 87 shares during the period. Vanguard Capital Wealth Advisors increased its position in Sarepta Therapeutics by 3.8% in the 4th quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock worth $236,000 after buying an additional 90 shares during the period. Riggs Asset Managment Co. Inc. increased its position in shares of Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares during the period. WCM Investment Management LLC increased its position in shares of Sarepta Therapeutics by 2.3% during the first quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock valued at $813,000 after purchasing an additional 142 shares during the period. Finally, New York Life Investment Management LLC increased its position in shares of Sarepta Therapeutics by 1.7% during the fourth quarter. New York Life Investment Management LLC now owns 9,942 shares of the biotechnology company’s stock valued at $959,000 after purchasing an additional 166 shares during the period. 86.68% of the stock is owned by institutional investors.

Insider Activity at Sarepta Therapeutics

In related news, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the sale, the executive vice president now owns 17,129 shares in the company, valued at $2,768,217.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Sarepta Therapeutics news, EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the sale, the executive vice president now directly owns 17,129 shares in the company, valued at $2,768,217.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Bilal Arif sold 7,859 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the sale, the insider now owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,451 shares of company stock worth $8,086,386. 7.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on SRPT shares. Barclays boosted their price objective on Sarepta Therapeutics from $185.00 to $226.00 and gave the company an “overweight” rating in a research report on Friday, June 21st. Oppenheimer upgraded Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $180.00 price objective on the stock in a research report on Tuesday, May 14th. JPMorgan Chase & Co. lowered their price objective on Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating on the stock in a research report on Friday, May 3rd. Piper Sandler restated an “overweight” rating and set a $205.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, July 1st. Finally, Citigroup lowered Sarepta Therapeutics from a “buy” rating to a “neutral” rating and boosted their price target for the company from $172.00 to $176.00 in a research note on Wednesday, June 26th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $187.72.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock traded down $0.52 on Friday, reaching $151.59. The company’s stock had a trading volume of 7,097 shares, compared to its average volume of 1,393,177. The business’s fifty day moving average price is $134.56 and its 200 day moving average price is $125.96. The company has a market cap of $14.33 billion, a price-to-earnings ratio of 1,382.82 and a beta of 0.89. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05. Sarepta Therapeutics, Inc. has a twelve month low of $55.25 and a twelve month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. The business had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The firm’s revenue was up 63.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.44) earnings per share. Equities analysts expect that Sarepta Therapeutics, Inc. will post 3.76 earnings per share for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.